{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T02:14:23Z","timestamp":1765332863359,"version":"3.46.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,9]]},"DOI":"10.7759\/cureus.98843","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T02:09:35Z","timestamp":1765332575000},"source":"Crossref","is-referenced-by-count":0,"title":["A Phase I Study of Nimotuzumab With Nivolumab in Advanced Non-small Cell Lung Cancer and Head and Neck Squamous Cell Cancer"],"prefix":"10.7759","author":[{"given":"Syed Ather","family":"Hussain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary E","family":"Reid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Frascati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrienne","family":"Groman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amparo","family":"Macias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia L","family":"Luaces","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orestes","family":"Santos-Morales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kalet","family":"Leon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tania","family":"Crombet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace K","family":"Dy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25516","article-title":"Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008","volume":"127","author":"Ferlay J","year":"2010","unstructured":"Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010, 127:2893-917. 10.1002\/ijc.25516","journal-title":"Int J Cancer"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2012.11.017","article-title":"A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC)","volume":"79","author":"Kim SH","year":"2013","unstructured":"Kim SH, Shim HS, Cho J, et al.. A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer. 2013, 79:270-5. 10.1016\/j.lungcan.2012.11.017","journal-title":"Lung Cancer"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-023-02990-y","article-title":"Recent advances in non-small cell lung cancer targeted therapy; an update review","volume":"23","author":"Araghi M","year":"2023","unstructured":"Araghi M, Mannani R, Heidarnejad Maleki A, et al.. Recent advances in non-small cell lung cancer targeted therapy; an update review. Cancer Cell Int. 2023, 23:162. 10.1186\/s12935-023-02990-y","journal-title":"Cancer Cell Int"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2019.02.001","article-title":"Combined checkpoint inhibition and chemotherapy: new era of 1st-line treatment for non-small-cell lung cancer","volume":"13","author":"Wang C","year":"2019","unstructured":"Wang C, Kulkarni P, Salgia R. Combined checkpoint inhibition and chemotherapy: new era of 1st-line treatment for non-small-cell lung cancer. Mol Ther Oncolytics. 2019, 13:1-6. 10.1016\/j.omto.2019.02.001","journal-title":"Mol Ther Oncolytics"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100355","article-title":"First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic Oncology","volume":"7","author":"Gridelli C","year":"2022","unstructured":"Gridelli C, Peters S, Mok T, Forde PM, Reck M, Attili I, de Marinis F. First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic Oncology. ESMO Open. 2022, 7:100355. 10.1016\/j.esmoop.2021.100355","journal-title":"ESMO Open"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2147\/LCTT.S16440","article-title":"Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer","volume":"2","author":"Takeda M","year":"2011","unstructured":"Takeda M, Okamoto I, Nishimura Y, Nakagawa K. Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer. Lung Cancer (Auckl). 2011, 2:59-67. 10.2147\/LCTT.S16440","journal-title":"Lung Cancer (Auckl)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21775","article-title":"Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro","volume":"119","author":"Blank C","year":"2006","unstructured":"Blank C, Kuball J, Voelkl S, et al.. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer. 2006, 119:317-27. 10.1002\/ijc.21775","journal-title":"Int J Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12632","article-title":"Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity","volume":"7","author":"Li CW","year":"2016","unstructured":"Li CW, Lim SO, Xia W, et al.. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 2016, 7:12632. 10.1038\/ncomms12632","journal-title":"Nat Commun"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.11.008","article-title":"Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation","volume":"63","author":"Ferris RL","year":"2018","unstructured":"Ferris RL, Lenz HJ, Trotta AM, et al.. Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation. Cancer Treat Rev. 2018, 63:48-60. 10.1016\/j.ctrv.2017.11.008","journal-title":"Cancer Treat Rev"},{"key":"ref10","article-title":"A phase I study of nimotuzumab with nivolumab in advanced non-small cell lung cancer or head and neck squamous cell cancer","author":"Hussain SA","year":"2024","unstructured":"Hussain SA, Reid M, Frascati R, et al.. A phase I study of nimotuzumab with nivolumab in advanced non-small cell lung cancer or head and neck squamous cell cancer. WCLC. 2024,","journal-title":"WCLC"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.02.003","article-title":"Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with stage IV non-small cell lung cancer","volume":"142","author":"Besse B","year":"2020","unstructured":"Besse B, Garrido P, Cortot AB, et al.. Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with stage IV non-small cell lung cancer. Lung Cancer. 2020, 142:63-9. 10.1016\/j.lungcan.2020.02.003","journal-title":"Lung Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.10.013","article-title":"Diminished efficacy of programmed death-(ligand)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status","volume":"17","author":"Ricciuti B","year":"2022","unstructured":"Ricciuti B, Arbour KC, Lin JJ, et al.. Diminished efficacy of programmed death-(ligand)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status. J Thorac Oncol. 2022, 17:399-410. 10.1016\/j.jtho.2021.10.013","journal-title":"J Thorac Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-009-0811-z","article-title":"KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy","volume":"17","author":"Siddiqui AD","year":"2010","unstructured":"Siddiqui AD, Piperdi B. KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy. Ann Surg Oncol. 2010, 17:1168-76. 10.1245\/s10434-009-0811-z","journal-title":"Ann Surg Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2024-CT032","article-title":"Abstract CT032: Promotive clinical effects of pembrolizumab with necitumumab in patients having advanced non-small cell lung cancer with PD-L1 expression of 50% or higher in a phase II study (K-TAIL-202)","volume":"84","author":"Horiike A","year":"2024","unstructured":"Horiike A, Wakui H, Sugawara S, et al.. Abstract CT032: Promotive clinical effects of pembrolizumab with necitumumab in patients having advanced non-small cell lung cancer with PD-L1 expression of 50% or higher in a phase II study (K-TAIL-202). Cancer Res. 2024, 84:CT032. 10.1158\/1538-7445.AM2024-CT032","journal-title":"Cancer Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck M","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, et al.. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016, 375:1823-33. 10.1056\/NEJMoa1606774","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0452","article-title":"Serial troponin for early detection of nivolumab cardiotoxicity in advanced non-small cell lung cancer patients","volume":"23","author":"Sarocchi M","year":"2018","unstructured":"Sarocchi M, Grossi F, Arboscello E, et al.. Serial troponin for early detection of nivolumab cardiotoxicity in advanced non-small cell lung cancer patients. Oncologist. 2018, 23:936-42. 10.1634\/theoncologist.2017-0452","journal-title":"Oncologist"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/419782-a-phase-i-study-of-nimotuzumab-with-nivolumab-in-advanced-non-small-cell-lung-cancer-and-head-and-neck-squamous-cell-cancer","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T02:09:37Z","timestamp":1765332577000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/419782-a-phase-i-study-of-nimotuzumab-with-nivolumab-in-advanced-non-small-cell-lung-cancer-and-head-and-neck-squamous-cell-cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.98843","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,9]]}}}